Celebrating four decades of precision dosing, PrecisePK connects directly to Epic, Cerner, and Sentri7 so patient data comes to clinicians and more time goes to patient care.

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- PrecisePK, a therapeutic drug monitoring (TDM) software company used by hospital systems worldwide, is highlighting its electronic health record (EHR) and clinical surveillance integrations this year, building on more than 40 years of precision dosing experience since launching from UC San Diego in 1985.

That foundation supports PrecisePK's continued efforts in direct EHR integration, which connects its dosing platform to the systems pharmacists already use every shift. Its integrations with Epic and Cerner (Oracle Health) automatically import vancomycin doses and administration times from the eMAR, along with serum creatinine results, patient demographics, vancomycin levels and specimen collection times; information pharmacists previously had to enter by hand.

That same principle extends to Sentri7®, Wolters Kluwer's clinical surveillance platform, which PrecisePK integrated with through a 2022 partnership. Pharmacists can launch PrecisePK directly from a patient's case within Sentri7, with demographics, dosing history and lab values carrying over automatically.

These integrations allow clinicians to move from the EHR to dosing recommendations without redundant logins or re-typed data, so the time saved on data entry goes back into patient care.

"Manual data entry isn't just a time cost for pharmacists, it's a point where errors can creep into patient care," said Anjum Gupta, CEO of PrecisePK. "More than 40 years ago, this company was built to make dosing decisions more precise. That same standard now applies to the data feeding those decisions, where every value that flows in through Epic, Cerner or Sentri7 is handled with the same rigor our clinical team applies to validating each drug model."

That rigor extends across the rest of the platform as well:

- Extensive Drug Coverage: Support for over 20 classes, including vancomycin, aminoglycosides, and select oncology and cardiology medications.

- Rigorous Validation: Each drug model is clinically validated by an internal team of clinical experts and partnered hospitals to ensure precision and reliability before market release.

- Seamless Implementation: A structured 4-to-7 week timeline covers pre-setup, configuration, and final clinical validation.

- Data Integrity: Strict adherence to HIPAA standards and data principles to ensure enterprise-grade security.

With over 40 years of experience in precision dosing, PrecisePK supports healthcare teams in 20+ countries in making safer, better-informed medication decisions. Looking ahead, PrecisePK remains committed to advancing precision dosing and helping clinicians deliver better patient care.

About PrecisePK

PrecisePK is a therapeutic drug monitoring software platform that provides personalized, model-informed dosing recommendations for vancomycin and other medications. Originally founded in 1985 as T.D.M.S. 2000, PrecisePK is backed by over 40 years of clinical use and has grown into a globally used precision dosing platform trusted by academic medical centers, community hospitals, and government health systems. PrecisePK is based in San Diego, California. For more information, visit www.precisepk.com.

SOURCE PrecisePK

Share this article